Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EBIT (2022 - 2025)

Historic EBIT for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to -$5.7 million.

  • Envoy Medical's EBIT fell 1480.29% to -$5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 465.21%. This contributed to the annual value of -$19.3 million for FY2024, which is 488.59% down from last year.
  • Latest data reveals that Envoy Medical reported EBIT of -$5.7 million as of Q3 2025, which was down 1480.29% from -$5.1 million recorded in Q2 2025.
  • Envoy Medical's 5-year EBIT high stood at -$901356.0 for Q2 2022, and its period low was -$6.7 million during Q4 2023.
  • Its 4-year average for EBIT is -$4.0 million, with a median of -$4.5 million in 2024.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 39702.89% in 2023, then soared by 3233.68% in 2024.
  • Over the past 4 years, Envoy Medical's EBIT (Quarter) stood at -$2.9 million in 2022, then plummeted by 131.35% to -$6.7 million in 2023, then soared by 32.34% to -$4.5 million in 2024, then dropped by 25.48% to -$5.7 million in 2025.
  • Its EBIT was -$5.7 million in Q3 2025, compared to -$5.1 million in Q2 2025 and -$5.1 million in Q1 2025.